Aaron Logan, MD – Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF)
Meet Aaron Logan, MD Associate Professor of Clinical Medicine at the University of California San Francisco, who presented on the use of MRD (Minimal Residual Disease) to guide therapy in adults with acute lymphoblastic leukemia. In the evolving landscape of leukemia treatment, with blinatumomab moving to the forefront and the ECOG nineteen ten study showcasing benefits for patients achieving MRD negativity at the level of ten to the minus four, Aaron highlights the increasing importance of MRD assessment using high sensitivity NGS (Next-Generation Sequencing).
REGISTER NOW TO JOIN US AT THESE UPCOMING LIVE EVENTS
AML-ALL US – Online content available – https://aml-allus2023.md-
AML-ALL EU – Registration open – https://aml-alleu2023.md-
MPN-MDS EU – registration open – https://mpn-mdseu2023.md-
This emerging approach presents an opportunity to gauge the depth of patients’ remissions accurately, potentially leading to decreased therapy duration or de-intensified treatment regimens. The prospect of improving patients’ quality of life and therapeutic outcomes in acute lymphoblastic leukemia holds excitement for the medical community.
Aaron Logan praises the conference’s unique format, where topics are narrowly assigned, but overlapping data is discussed, allowing for diverse opinions and interpretations from various experts. The event fosters valuable discussions and provides insights into how data can be applied to real-world scenarios, making it highly valuable for attendees.
Having attended the conference previously, Aaron expresses admiration for the quality of presentations and discussions, making this focused meeting a must-attend event for him. The conference offers a distinct opportunity to explore cutting-edge advancements and gather diverse perspectives on acute leukemia treatment, making it a truly valuable and enriching experience.